DYADIC INTERNATIONAL INC Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- DYADIC INTERNATIONAL INC treasury stock, value, acquired, cost method for fiscal 2018 was $2.30M, a 62.98% decline from fiscal 2017.
- DYADIC INTERNATIONAL INC treasury stock, value, acquired, cost method for fiscal 2017 was $6.22M, a 40.17% decline from fiscal 2016.
- DYADIC INTERNATIONAL INC treasury stock, value, acquired, cost method for fiscal 2016 was $10.40M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2018-12-31 | $2.30M 10-K · filed 2020-03-30 | |
| 2017-12-31 | $6.22M 10-K · filed 2019-03-27 | |
| 2016-12-31 | $10.40M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |